Navigation Links
DART Therapeutics Initiates Study of HT-100 For Duchenne Muscular Dystrophy
Date:7/15/2013

CAMBRIDGE, Mass., July 15, 2013 /PRNewswire/ --DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), has initiated a phase 1b/2a study of its lead drug candidate, HT-100 (delayed-release halofuginone). The phase 1b study (with a six-month 2a extension) in patients will determine the safety and tolerability of different, increasing doses of HT-100, and explore trends in a range of efficacy endpoints.    

HT-100 is an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle fiber regeneration in boys with DMD. The phase 1b/2a clinical program will enroll 30 boys and young men with DMD, both ambulatory and non-ambulatory. Participating centers include University of California, Davis Medical Center (Sacramento, Calif.), Kennedy Krieger Institute, Johns Hopkins School of Medicine (Baltimore, MD), Washington University School of Medicine (St. Louis, MO), Cincinnati Children's Hospital Medical Center (Cincinnati, Ohio) and Nationwide Children's Hospital (Columbus, Ohio). DART expects to complete the study in mid 2014.

"Treating DMD requires a cocktail of therapies that will change over time," said Gene Williams, CEO of DART Therapeutics. "We believe HT-100 could be a valuable part of this cocktail—even a mini-cocktail on its own—because it demonstrates potential to address many different aspects of the disease in parallel, which could make it an exceptionally important therapy for all boys living with DMD."

DART's study will include boys aged six through 20, an atypical age range that allows investigators to evaluate HT-100's safety in a broad population as well as study its effect in different disease stages. Researchers will also evaluate a new endpoint that could make DMD studies faster, more precise, less expensive and inclusive of a larger group of boys. Presently, the six-minute walk (6MW) is the standard endpoint for DMD studies. However, the 6MW has shortcomings including variability and difficulty interpreting the clinical relevance of a given effect size. It also limits study participants to boys who can walk at a certain speed. There are no validated endpoints for very young boys with DMD. The proposed endpoint, electrical impedance myography (EIM), is a simple, non-invasive technique that can measure the health of a muscle and track its changes over time. As a validated endpoint for DMD, EIM would allow researchers to include a wide range of boys in studies and more effectively and rapidly understand how well a treatment is working to halt disease progression.

"Not only do we need several different categories of treatments for DMD—a therapeutic cocktail that might include different components depending on the stage of the disease—we also need new endpoints to improve the quality and speed of our clinical studies," said Dr. Diana Escolar, Associate Professor of Neurology at Johns Hopkins School of Medicine's Kennedy Krieger Institute, DART's Chief Medical Officer and Study Director. "It is only through this two-pronged approach that we will succeed in our mission to make DMD a chronic, manageable disease instead of a fatal one."

Affecting approximately 1 in 3,600 boys worldwide, DMD is the most common of the muscular dystrophies and the most lethal genetic disorder of childhood. It is caused by a genetic mutation that renders boys unable to make functional dystrophin, a protein critical for normal muscle function. Young men with DMD show progressive signs of physical impairment as early as age three, lose the ability to walk in their teens, and die of cardiac or respiratory failure in their late twenties or early thirties. HT-100 may help promote healthy muscle regeneration, reduce inflammation and the resulting damage to muscle, and decrease the scar tissue that forms in the muscles of boys with DMD. The drug candidate has Orphan Drug Status in the U.S. and EU.

The study sponsor, Halo Therapeutics, is a subsidiary of DART Therapeutics. More information is available at clinicaltrials.gov, identifier NCT01847573 or via the following link: http://www.clinicaltrials.gov/ct2/show/NCT01847573.

About DART Therapeutics

DART Therapeutics Inc., Cambridge, Mass., is a biotechnology firm applying a new model for drug development to rare pediatric neuromuscular diseases. In the DART model, patient foundations join with biotechnology industry veterans to impact a central problem in rare diseases: Rapid therapy development. DART is focused on Duchenne muscular dystrophy, a fatal neuromuscular disease for which there is no effective treatment. For more information, please visit www.dartrx.com.

Media Contact: 
Shanti Skiffington 
617.921.0808 
shanti.skiffington(at)gmail.com

 


'/>"/>
SOURCE DART Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
2. Global Antiviral Therapeutics Report - Technologies, Markets and Companies - 2013-2022
3. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
4. Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
5. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
6. Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings
7. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... , May 17, 2017  Bayer announced today ... portfolio will be presented at the 53 rd ... (ASCO), taking place June 2-6 in Chicago ... at ASCO span prostate, colorectal, liver and thyroid cancers, ... from the Phase II CHRONOS-1 trial of copanlisib in ...
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) announced today ... ended April 1, 2017 .   GAAP diluted earnings ... the prior year period as the sale of the ... non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue of ... terms.  Excluding the effects of blood screening and the ...
(Date:5/9/2017)... Ind. , May 9, 2017 Zimmer ... leader in musculoskeletal healthcare, today announced it has earned ... Employers of 2017" list. The Company was ranked among ... of Large Employers and Healthcare Equipment and Services. ... employers based on an anonymous, independent survey of over ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare professionals gained ... was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , ... of independent hearing healthcare providers to help them stay ahead in the industry. At ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to ... campaign in USA Today, which will educate readers on how to take care of ... a large focus is placed on melanoma. Dancing with the Stars professional, Witney Carson, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs ... on May 30th and 31st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s ... Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for chronic ... introduce the most powerful SCS system and the only stretchable lead on the market. ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
Breaking Medicine News(10 mins):